Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jan;84(1):161-163.
doi: 10.1016/j.jaad.2020.08.095. Epub 2020 Aug 26.

Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic

Maha N Syed  1 , Mohsin Shah  2 , Daniel B Shin  1 , Marilyn T Wan  1 , Kevin L Winthrop  3 , Joel M Gelfand  4
Affiliations

Effect of anti-tumor necrosis factor therapy on the risk of respiratory tract infections and related symptoms in patients with psoriasis-A meta-estimate of pivotal phase 3 trials relevant to decision making during the COVID-19 pandemic

Maha N Syed et al. J Am Acad Dermatol. 2021 Jan.
No abstract available

PubMed Disclaimer

Figures

Fig 1
Fig 1
Meta-estimate of respiratory tract infections from publications of US Food and Drug Administration–approved dosages of phase 3 pivotal trials adverse events tables (includes “upper respiratory tract infections,” “nasopharyngitis,” “rhinitis,” “rhinorrhea,” “pneumonia,” bronchitis,” “sinusitis,” “pharyngitis,” “flu syndrome,” and “cough”). CI, Confidence interval; REML, restricted maximum likelihood.
Fig 2
Fig 2
Meta-estimate of respiratory tract infections from publications of US Food and Drug Administration–approved dosages of phase 3 pivotal trials adverse events tables (includes “upper respiratory tract infections,” “nasopharyngitis,” “rhinitis,” “rhinorrhea,” “pneumonia,” “bronchitis,” “sinusitis,” “pharyngitis,” “flu syndrome,” and “cough”). CI, Confidence interval; REML, restricted maximum likelihood.
See this image and copyright information in PMC

References

    1. Wan M.T., Shin D.B., Winthrop K.L., Gelfand J.M. The risk of respiratory tract infections and symptoms in psoriasis patients treated with IL-17-pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. J Am Acad Dermatol. 2020;83:677–679. - PMC - PubMed
    1. Syed M.N., Shin D.B., Wan M.T., Winthrop K.L., Gelfand J.M. The risk of respiratory tract infections in psoriasis patients treated with IL-23-pathway inhibiting biologics: a meta-estimate of pivotal trials relevant to decision-making during the COVID-19 pandemic. J Am Acad Dermatol. 2020 doi: 10.1016/j.jaad.2020.06.1014. - DOI - PMC - PubMed
    1. Feldmann M., Maini R.N., Woody J.N., et al. Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020;395:1407–1409. - PMC - PubMed
    1. Gianfrancesco M., Hyrich K.L., Al-Adely S., et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry. Ann Rheum Dis. 2020;79:859–866. - PMC - PubMed
    1. Lythgoe M.P., Middleton P. Ongoing clinical trials for the management of the COVID-19 pandemic. Trends Pharmacol Sci. 2020;41:363–382. - PMC - PubMed

MeSH terms

Substances